Business Context and Reporting Period
This Form 8-K is filed by Pro-Pharmaceuticals, Inc. (noting the metadata reference to Galectin Therapeutics Inc appears to be a discrepancy, as the filing text explicitly identifies Pro-Pharmaceuticals, Inc.) on November 4, 2009. The report details a subsequent closing under a Securities Purchase Agreement originally entered into on February 12, 2009, with 10X Fund, L.P.
Key Financial Metrics
- Gross Proceeds: $310,000 raised in the November 4, 2009 closing.
- Net Proceeds: Approximately $296,000 after reimbursement of purchaser expenses and a 3% origination fee.
- Securities Issued:
- 155,000 shares of Series B-2 Preferred Stock (convertible into 620,000 shares of Common Stock).
- Class A-1 Warrants exercisable for 310,000 shares of Common Stock.
- Class A-2 Warrants exercisable for 310,000 shares of Common Stock.
- Class B Warrants exercisable for 1,240,000 shares of Common Stock.
- Total Placement Progress: This tranche brings the total raised under the private placement to $4.1 million of a potential $6 million.
Material Changes and Agreements
The filing reports the execution of a Letter Agreement on August 11, 2009, which amended the original Purchase Agreement. Key changes include:
- Extension of Final Purchase Date: Extended from August 11, 2009, to February 11, 2010.
- Redemption Rights: Holders of Series B-1 Preferred Stock may require redemption on or after September 12, 2010. Holders of Series B-2 Preferred Stock may require redemption two years from issuance.
- Default Conversion: If the Company fails to pay the redemption price in cash, holders may automatically convert shares into a promissory note bearing 15% annual interest, secured by a lien on all Company assets.
Outlook, Risks, and Contingencies
- Liquidity Risk: The Company relies on the continued funding of the private placement to meet obligations. The final closing date is now February 11, 2010.
- Debt Contingency: The potential conversion of preferred stock into secured debt at 15% interest represents a significant financial obligation if the Company cannot fund redemptions.
- Regulatory Status: Securities were issued under Section 4(2) of the Securities Act and Rule 506 of Regulation D; they are "restricted securities" and not registered.
Investor Verification Checklist
- Verify the total capital raised to date ($4.1 million) against the Company's current cash burn rate and runway.
- Confirm the Company's ability to meet the February 11, 2010 final purchase date or negotiate further extensions.
- Assess the impact of the 15% interest rate promissory note contingency on future financial statements if redemption is triggered.
- Review the dilution impact of the 2,480,000 shares of Common Stock underlying the warrants issued in this specific tranche.